Literature DB >> 16343508

Coagulation and atherothrombotic disease.

Ramzi Ajjan1, Peter J Grant.   

Abstract

Atherothrombotic disease arises secondary to a complex gene-environment interaction. In the initial stages, the condition is clinically silent but with more advanced disease, an occlusive thrombus is formed resulting in the classical clinical manifestations. Both environmental factors and genetic variations in elements of the clotting cascade influence thrombosis risk by inducing quantitative and qualitative changes in the mature protein, which may affect the final structure of the clot and determine its resistance to lysis. Understanding the fine details of gene-environment interactions in relation to thrombus formation will help to shed more light on disease pathogenesis. Consequently, this will allow the development of more efficacious treatment strategies and will also help to identify subjects at risk, thereby enabling the introduction of early preventative measures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343508     DOI: 10.1016/j.atherosclerosis.2005.10.042

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  23 in total

Review 1.  Old and new molecular mechanisms associated with platelet resistance to antithrombotics.

Authors:  Antonio J López Farré; Juan Tamargo; Petra J Mateos-Cáceres; Luís Azcona; Carlos Macaya
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

2.  Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.

Authors:  Joanna Lecka; Manjit Singh Rana; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Aspirin resistance and diabetes mellitus.

Authors:  R Ajjan; R F Storey; P J Grant
Journal:  Diabetologia       Date:  2008-03       Impact factor: 10.122

Review 4.  The pathophysiology, diagnosis and treatment of the acute coagulopathy of trauma and shock: a literature review.

Authors:  J Kaczynski; M Wilczynska; L Fligelstone; J Hilton
Journal:  Eur J Trauma Emerg Surg       Date:  2013-12-12       Impact factor: 3.693

5.  Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial.

Authors:  Chit Moy Ley; Qing Ni; Xing Liao; Huai-Lin Gao; Nicola Robinson
Journal:  Chin J Integr Med       Date:  2016-07-13       Impact factor: 1.978

6.  A comparative study of the antithrombotic effect through activated endothelium of garlic powder and tomato extracts using a rodent model of collagen and epinephrine induced thrombosis.

Authors:  Leeseon Kim; Yeni Lim; Soo-Yeon Park; You Jin Kim; Oran Kwon; Jin Hee Lee; Jae-Ho Shin; Yoon Kyoung Yang; Ji Yeon Kim
Journal:  Food Sci Biotechnol       Date:  2018-09-18       Impact factor: 2.391

7.  Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.

Authors:  Christoph B Olivier; Patrick Weik; Melanie Meyer; Susanne Weber; Philipp Diehl; Christoph Bode; Martin Moser; Qian Zhou
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

8.  Association between variations in coagulation system genes and carotid plaque.

Authors:  David Della-Morte; Ashley Beecham; Chuanhui Dong; Liyong Wang; Mark S McClendon; Hannah Gardener; Susan H Blanton; Ralph L Sacco; Tatjana Rundek
Journal:  J Neurol Sci       Date:  2012-09-13       Impact factor: 3.181

Review 9.  Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

Authors:  R J King; P J Grant
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

Review 10.  Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.

Authors:  Sameer A Kassem; Itamar Raz
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.